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Clinical trials have reported conflicting results on whether oral clodronate therapy improves survival in breast cancer patients. This
study was undertaken to evaluate further the effect of oral clodronate therapy on overall survival, bone metastasis-free survival and
nonskeletal metastasis-free survival among breast cancer patients. An extensive literature search was undertaken for the period 1966
to July 2006 to identify clinical trials examining survival in breast cancer patients who received 2 or 3 years of oral clodronate therapy
at 1600mgday
 1 compared with those without therapy. Meta-analyses were carried out separately for patients diagnosed with
advanced breast cancer and early breast cancer. Our meta-analysis found no evidence of any statistically significant difference in
overall survival, bone metastasis-free survival or nonskeletal metastasis-free survival in advanced breast cancer patients receiving
clodronate therapy or early breast cancer patients receiving adjuvant clodronate treatment compared with those who did not receive
any active treatment.
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Bone is the most common site of distant recurrence in breast cancer
and affects an estimated 70% of women with advanced breast cancer
(Lipton, 2003). Bone metastases results in not only skeletal-related
events such as pathological fractures and spinal cord compression,
but also a reduction in survival (Coleman, 1997). Treatment for
breast cancer that has metastasised to the bone can improve quality
of life, but the cancer is incurable. Therefore, it is important to
investigate ways of preventing or delaying bone metastasis.
Randomised clinical trials, comparing bisphosphonates, such as
clodronate, with either placebo or no treatment, have shown a
reduction in skeletal complications and skeletal-related events from
bone metastases (Kristensen et al, 1999; Powles et al, 2006).
In patients with early breast cancer, clodronate is currently the
only bisphosphonate shown to improve survival and to reduce the
incidence of bone metastases in randomised controlled trials
(Diel et al, 1998; Dando and Wiseman, 2004; Powles et al, 2006).
However, clinical trials have not shown a clear positive impact
on breast cancer survival with a range of conflicting opinion
remaining (Elomaa et al, 1988; Kanis et al, 1996; Diel et al, 1998;
Kristensen et al, 1999; Mardiak et al, 2000; Saarto et al, 2001;
Powles et al, 2006). In terms of overall survival, two trials found a
statistically significant longer overall survival for breast cancer
patients who received adjuvant clodronate (Diel et al, 1998; Powles
et al, 2006) whereas one trial found a statistically significant
shorter overall survival (Saarto et al, 2001). Two trials found a
statistically significant longer bone metastasis-free survival for
those who received adjuvant clodronate (Diel et al, 1998; Powles
et al, 2006) whereas one trial found no difference (Saarto et al,
2001). In advanced breast cancer patients, one trial suggests a
delayed time to bone metastasis formation (Kanis et al, 1996)
whereas another trial did not (Mardiak et al, 2000). In terms of
nonskeletal metastasis-free survival, the results were ambivalent
with two trials finding a statistically significant longer nonskeletal
metastasis-free survival for those receiving adjuvant clodronate
(Diel et al, 1998; Saarto et al, 2001) whereas one did not (Powles
et al, 2006). These conflicting results demand the conduct of a
meta-analysis to determine the effect of oral clodronate therapy on
breast cancer survival.
The purpose of this study is to examine the effect of oral
clodronate 1600mgday
 1 given for 2 or 3 years for breast cancer
patients in terms of overall survival, bone metastasis-free survival
and nonskeletal metastasis-free survival, in addition to their
standard surgery, radiotherapy, chemotherapy or hormone
therapy by means of meta-analysis using aggregate patient data.
MATERIALS AND METHODS
Types of trials
Trials included randomised clinical trials that investigated overall,
bone metastasis-free or nonskeletal metastasis-free survival among
breast cancer patients receiving oral clodronate therapy or no
active treatment (Table 1).
Types of participants
Participants were patients with histologic- or cytologic-proven
breast cancer but no prior history of other malignant diseases
(besides recurrent breast cancer) or bisphosphonate usage. In this
study, advanced breast cancer was defined as patients who had
either recurrent breast cancer or metastatic breast cancer (not
primary breast cancer) at the time of enrolment in the study
(Elomaa et al, 1988; Kanis et al, 1996; Kristensen et al, 1999;
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sMardiak et al, 2000). Early breast cancer was defined as patients
who were diagnosed with primary operable breast cancer (Diel
et al, 1998; Saarto et al, 2001; Powles et al, 2006).
Types of interventions
The types of interventions were oral clodronate 1600mgday
 1
given for either 2 or 3 years, compared with an identical placebo or
no treatment.
Types of outcome measures
Outcome measures included for 5-year overall, bone metastasis-
free and nonskeletal metastasis-free survival (Table 2).
Search strategy for identifying trials
A comprehensive search was conducted for relevant published
primary trials using the following online electronic bibliographic
databases until the 7th of July 2006 with no language restriction:
PubMed from 1950 to 2006, Journals@Ovid Full text from 1993
to 2006, SCOPUS from 1966 to 2006, COCHRANE database of
systematic reviews until the second quarter of 2006 and Cochrane
Central Register of Controlled Trials until the second quarter of
2006, LILACS from 1982 to 2006. The search terms employed were
clodronate, breast cancer, survival, mortality and trial. A manual
search was conducted of the following journals: Breast Cancer
Research and Treatment (1981 t0 July 2006), Clinical Oncology
(1989 to July 2006), Breast Cancer Research (1999 to June 2006),
Table 1 Summary of the included phase III trials investigating clodronate and breast cancer survival
Study Group
No. of
subjects
Median age (years)
(range) Patient population
Early breast cancer
Diel et al (1998) Control 145 51 (24–78) Primary breast cancer stage T1, T2, T3 or T4 and histologically classified
as N0, N1, N2. At least one tumour cell in bone marrow aspirate
Treatment 157 51 (24–78)
Saarto et al (2001) Control 143 52
a Primary node positive breast cancer, operable breast cancer,
histologically proven axillary metastases (T1 to T3, N1/2, MO)
Treatment 139 52
a
Powles et al (2002) Control 539 53
a710.6 (s.d.) Primary operable breast cancer, no metastatic disease
Treatment 530 53
a710.5 (s.d.)
Advanced breast cancer
Elomaa et al (1988) Control 17 Not available Normocalcaemic with multiple osteolytic bone metastases
Treatment 17 Not available
Paterson et al (1993) Control 88 61 (33–74) Breast cancer patients with metastatic skeletal disease
Treatment 85 58 (26–77)
Kanis et al (1996) Control 67 59 (32–82) Histologically proven breast cancer and recurrent disease, absence of
skeletal metastases
Treatment 66 58 (30–76)
Kristensen et al (1999) Control 51 53 (34–74) Histologically proven breast cancer and recurrence in bone either
histologically or on X-ray.
Treatment 49 53 (34–71)
Mardiak et al (2000) Control 33 55 (30–79) Histologically or cytologically proven breast cancer, previously
untreated locally advanced (point 45cm) or metastastic breast cancer
without skeletal and CNS involvement
Treatment 30 55 (30–79)
CNS¼central nervous system.
aRefers to mean ages.
Table 2 List of individual studies with overall survival, bone metastasis-free survival and nonskeletal metastasis-free survival
HR (95% CI)
Study Overall survival Bone metastasis-free survival Nonskeletal metastasis-free survival
Early breast cancer
Diel et al (1998) 0.26 (0.13, 0.55) 0.36 (0.18, 0.71) 0.38 (0.20, 0.72)
Powles et al (2002) 0.77 (0.59, 1.00) 0.69 (0.48, 0.99) 0.84 (0.62, 1.13)
Saarto et al (2001) 1.90 (1.17, 3.08) 1.26 (0.65, 2.46) 2.05 (1.25, 3.36)
Advanced breast cancer
Elomaa et al (1988) 0.27 (0.11, 0.66) Not available Not available
Kanis et al (1996) 0.92 (0.59, 1.42) 0.52 (0.27, 1.02) Not available
Kristensen et al (1999) 0.99 (0.57, 1.73) Not available Not available
Mardiak et al (2000) 0.73 (0.38, 1.41) 2.11 (0.22, 20.34) 1.07 (0.41, 2.77)
CI¼confidence interval; HR¼hazard ratio.
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sBritish Journal of Cancer (1999 to July 2006) and Journal of Clinical
Oncology (1983 to July 2006). Proceedings of international
meetings (Bi-annual meetings of the American Society of Clinical
Oncology, The European Society for Medical Oncology, The
European Cancer Conference and The San Antonio Breast Cancer
Symposium) were searched for any relevant trials. Reference lists
of primary articles and reviews were also searched for additional
trials (Pavlakis et al, 2005). Authors of the trials were contacted to
identify any missing or unpublished trials.
Critical evaluation of the selected trials
The study types included in the systematic review were phase III
clinical trials of oral clodronate therapy and survival in breast
cancer patients. We identified and reviewed eligible articles
independently to minimise the risk of selection bias and final
decisions were reached by consensus. Trials that examined overall,
bone metastasis-free or nonskeletal metastasis-free survival were
included in our meta-analysis.
Data abstraction
The authors independently reviewed and abstracted the informa-
tion and data using standardised data forms. Abstraction included
information on pertinent methodological aspects of the study
design, demographic characteristics of the participants and patient
population recruited to the trial.
Whenever possible, the following information was extracted
from the publications: (1) the number of patients involved in the
treatment and control groups; (2) the hazard ratio (HR) with 95%
confidence interval (CI) for 5-year overall, bone metastasis-free
and nonskeletal metastasis-free survival. With observed death
cases for both groups, HR with 95% CI were estimated using the
method described by Parmar et al (1998) if a P-value from the
comparison of two overall survival (Elomaa et al, 1988; Kristensen
et al, 1999; Mardiak et al, 2000; Saarto et al, 2001) or other survival
curves (Kanis et al, 1996; Kristensen et al, 1999) was provided or if
event rates for treatment and control groups were available (Kanis
et al, 1996) or could be derived by assuming exponential survival
distribution (Paterson et al, 1993). Sometimes, Kaplan–Meier
curves or survival tables were provided instead of HR and 95% CI,
in this case, HRs with 95% CI were estimated from Kaplan–Meier
curves using the method described by Parmar et al (1998) with the
number of patients at risk at the beginning of the study (Kanis
et al, 1996; Mardiak et al, 2000; Saarto et al, 2001) or the method
described by Williamson et al (2002) with the number of patients
at risk at some time points during the period of follow-up (Diel
et al, 1998; Kristensen et al, 1999). If HR and 95% CI can be
estimated for less than or greater than 5-year survival (Elomaa
et al, 1988; Paterson et al, 1993; Kanis et al, 1996; Kristensen et al,
1999; Mardiak et al, 2000; Powles et al, 2006) instead of exact
5-year survival, constant HR was assumed and this HR together
with its 95% CI were used as an estimate of the 5-year survival HR
and 95% CI. If the estimated HR and 95% CI derived were not
consistent with the conclusions of the published paper, then the
data for the particular paper were excluded (Paterson et al, 1993).
Statistical analysis
Funnel plots, together with Begg’s rank correlation test and Egger’s
regression asymmetry test were used to assess publication bias
(Sutton et al, 2000). In addition, the Duval and Tweedie
nonparametric ‘trim and fill’ method of accounting for publication
bias was performed to formalise the use of funnel plots and adjust
the meta-analysis by incorporating the theoretical missing trials
(Sutton et al, 2000).
Q-statistic was used to investigate the degree of heterogeneity
between trials. A P-value of o0.1 was interpreted as evidence of
heterogeneity among the combined trials than would be expected
by chance alone. I
2-statistical test (Higgins and Thompson, 2002)
was carried out to describe the proportion of total variation caused
by heterogeneity because the Q-statistic has low power in common
situations of few studies and excessive power to detect clinically
unimportant heterogeneity when there are many studies (Hardy
and Thompson, 1998). I
2 of less than 30% of the variability in point
estimate was considered as mild heterogeneity, more than 50% was
notable heterogeneity, whereas in between was considered as
moderate heterogeneity. In our study, the I
2-statistic found notable
heterogeneity; therefore pooled estimates were derived using a
random effects model (DerSimonian–Laird method) to account
for interstudy heterogeneity. Meta-analyses were performed in
patients who received adjuvant clodronate treatment and in
patients who received clodronate treatment for their advanced
disease, compared with those who received no active treatment.
All analyses were performed using STATA version 7 (Stata Corp.,
College Station, TX, USA).
RESULTS
Of the articles identified, 13 trials investigated overall survival,
bone metastasis-free survival or nonskeletal metastasis-free
survival. Among these, Elomaa et al (1987, 1988) reported the
same results from the same patients and therefore only Elomaa
et al (1988) was included. Powles et al (2002), Atula et al (2003)
and Powles et al (2006) reported results from the same group of
patients, only one (Powles et al (2006)) reported 5-year overall
survival, 5-year bone metastasis-free survival and 5-year non-
skeletal metastasis-free survival and was included in our meta-
analysis. The study by Saarto et al (2004) was an extended 10-year
follow-up of patients from the study by Saarto et al (2001), whereas
Leppa et al (2005) investigated the influence of clodronate
treatment on serum postoperative matrix metalloproteinase-2
associated with the clinical outcome of the same group of patients,
thus only one study (Saarto et al, 2001) where HR and 95% CI
could be derived was included in our study. Therefore, eight trials
were considered in our study (Table 1). However, only seven
studies (Table 2) were included in our meta-analysis because the
estimated HR and 95% CI from the published data of one study
(Paterson et al, 1993) was not consistent with the reported
conclusion of the study and therefore this particular study was
excluded from our meta-analysis. Among these, three studies
investigated adjuvant clodronate treatment in patients diagnosed
with early breast cancer (Diel et al, 1998; Saarto et al, 2001; Powles
et al, 2006), whereas four studies investigated clodronate treatment
in advanced breast cancer patients (Elomaa et al, 1988; Kanis et al,
1996; Kristensen et al, 1999; Mardiak et al, 2000).
Overall survival
Both Begg’s rank correlation test (P¼0.37) and Egger’s regression
asymmetry test (P¼0.46) did not find any significant publication
bias in our meta-analysis; however, funnel plots suggest otherwise.
Early breast cancer
The Q-statistic showed the presence of heterogeneity among
different trials included in our meta-analysis (Po0.001). I
2-
statistics also found notable heterogeneity (Table 3). Compared
with breast cancer patients without clodronate treatment, Diel et al
(1998) and Powles et al (2006) reported a statistically significant
increase in overall survival for patients receiving adjuvant
clodronate treatment (Table 2), whereas Saarto et al (2001) found
the opposite trend (Table 2). The pooled result demonstrated no
statistically significant difference in the overall survival between
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spatients treated with adjuvant clodronate therapy and those
receiving no treatment (HR¼0.75, 95% CI¼0.31, 1.82) (Figure 1).
Advanced breast cancer
Both Q-statistic and I
2-statistic demonstrated the presence of
notable heterogeneity among the trials when only advanced breast
cancer patients were included (Table 2). Meta-analysis showed that
clodronate did not change the overall survival among patients with
advanced breast cancer (HR¼0.73, 96% CI¼0.46, 1.14).
Bone metastasis-free survival
Five trials investigated bone metastasis-free survival among breast
cancer patients receiving clodronate treatment or no active
treatment (Kanis et al, 1996; Diel et al, 1998; Mardiak et al,
2000; Saarto et al, 2001; Powles et al, 2006). Begg’s rank correlation
test (P¼1.00), Egger’s regression asymmetry test (P¼0.77) and
funnel plots did not find any significant publication bias in our
meta-analysis.
Early breast cancer
When analysis was restricted to those receiving adjuvant
clodronate treatment, both Q-statistic and I
2 statistic detected the
presence of notable heterogeneity among the trials (Table 2).
Pooled analysis did not find any statistically significant difference
in the time to appearance of bone metastasis in patients who
received adjuvant clodronate treatment compared with those who
did not (HR¼0.68, 95% CI¼0.38, 1.23) (Figure 2).
Advanced breast cancer
Our meta-analysis suggested no difference in the appearance of
bone metastasis between advanced breast cancer patients who
received clodronate therapy and those who did not (HR¼0.68,
95% CI¼0.23, 1.98).
Nonskeletal metastasis-free survival
Four trials provided information on nonskeletal metastasis-free
survival (Diel et al, 1998; Mardiak et al, 2000; Saarto et al, 2001;
Powles et al, 2006). Among these four trials, Diel et al (1998)
reported that adjuvant clodronate treatment delayed the occur-
rence of nonskeletal metastasis, whereas Saarto et al (2001) found
the opposite trend. Begg’s rank correlation test (P¼1.00), Egger’s
regression asymmetry test (P¼0.99) and funnel plots did not
establish any significant publication bias.
Early breast cancer
Our meta-analysis demonstrated no statistically significant delay
in the occurrence of nonskeletal metastases between patients
receiving adjuvant clodronate therapy and those receiving no
treatment (HR¼0.89, 95% CI¼0.40, 1.98) (Figure 3).
DISCUSSION
Our meta-analysis examined the effects of clodronate on 5-year
overall, bone metastasis-free and nonskeletal metastasis-free
survival among early breast cancer patients receiving adjuvant
clodronate treatment and advanced breast cancer patients. There
was no evidence to suggest that clodronate therapy improves
Table 3 Meta-analysis of overall survival, bone metastasis-free survival and nonskeletal metastasis-free survival
No. of subjects
Meta-analysis Control Treatment Heterogeneity (P-value) I
2 (%) HR (95% CI)
Overall survival
Advanced breast cancer only 456 458 o0.001 82 0.71 (0.40, 1.26)
Adjuvant clodronate treatment 827 826 o0.001 91 0.75 (0.31, 1.82)
Bone metastasis-free survival
Advanced breast cancer only 388 392 0.044 63 0.68 (0.34, 1.36)
Adjuvant clodronate treatment 827 826 0.037 70 0.68 (0.38, 1.23)
Nonskeletal metastasis-free survival
Advanced breast cancer only 321 326 o0.001 88 0.95 (0.31, 2.91)
Adjuvant clodronate treatment 827 826 o0.001 89 0.89 (0.40, 1.98)
CI¼confidence interval; HR¼hazard ratio.
HR
0.1 1 2 4
 Combined
Powles et al (2006)
 Saarto et al (2001)
 Diel et al (1998)
Favours clodronate  Favours placebo 
Figure 1 Forest plot of overall survival in early breast cancer patients
receiving adjuvant clodronate therapy.
HR
0.1 1 2 4
 Combined
 Powles et al (2006)
 Saarto et al (2001)
 Diel et al (1998)
Favours clodronate  Favours placebo 
Figure 2 Forest plot of bone metastasis-free survival in early breast
cancer patients receiving adjuvant clodronate therapy.
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free survival significantly in either group of patients. However,
larger trials may be worthwhile conducting to assess the true effect
of clodronate, as currently there are a limited number of trials and
patients.
Potential limitations exist because of the availability, quality and
heterogeneity of the published data. In our analyses, we assumed
constant HR and used this together with its 95% CI if an estimate
for 5-year survival could not be derived from the available data, as
was the case for overall survival (Elomaa et al, 1988; Kanis et al,
1996; Diel et al, 1998; Mardiak et al, 2000; Powles et al, 2006).
Imposing more stringent criteria by including only 5-year survival
would not alter the trend of the effect of clodronate on survival
among either early or advanced breast cancer patients. Further-
more, all individual trials included in our study compared
clodronate therapy with an equivalent placebo except one (Diel
et al, 1998). Sensitivity analysis by excluding this trial among
adjuvant studies did not lead to a different conclusion. This
suggests that the trial design with placebo or without placebo may
not affect the results in terms of survival.
Patients received surgery, radiotherapy and adjuvant systemic
therapy according to local protocols. No assessment of any
treatment with tamoxifen or aromatase inhibitor therapy was
conducted among two trials (Elomaa et al, 1988; Kanis et al, 1996)
when such therapies are known to prolong survival in hormone-
positive breast cancer patients (Goss et al, 2005; Thurlimann et al,
2005; Kaufmann and Rody, 2006; Wardley, 2006). Although
traditional prognostic factors were well balanced (such as age,
menopausal status and tumour size), other confounding factors
such as progesterone receptor status were not balanced (Saarto
et al, 2001) and the oestrogen receptor status is unknown in the
patient population of three trials (Elomaa et al, 1988; Kanis et al,
1996; Mardiak et al, 2000). Such factors would contribute to the
heterogeneity of our study to some extent. Therefore, the random-
effects model only was adopted in our analysis to consider the
heterogeneity by providing a wider CI.
Publication bias is a well-known limitation of meta-analyses. To
adjust for publication bias, the Duval and Tweedie nonparametric
‘trim and fill’ method was adopted. Meta-analysis with or without
the ‘trim and fill’ method did not result in different conclusions,
indicating that our results are statistically robust.
In conclusion, the use of oral clodronate in breast cancer
patients does not significantly increase 5-year overall, nonskeletal
metastasis-free or bone metastasis-free survival in early breast
cancer patients receiving adjuvant clodronate treatment or
patients receiving clodronate for their advanced breast cancer.
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